IBM CEO: “I believe [AI] is Going to Infuse Every Enterprise.”

IBM Chairman and CEO Arvind Krishna says artificial intelligence is the future to unlocking a growing demand for data for the next century. Watch below to hear more of Arvind Krishna’s thoughts on the future of AI and the potential impact it could have on the business community as a whole.

 

 

“I believe [AI] that is going to infuse every enterprise [and] every process in this century.”

 

Krishna: So if you think about AI, I’ll begin with a bit of catch phrase, the same way as electricity helped electrification at the turn of the last century, I believe that is going to infuse every enterprise [and] every process in this century. So now that said, let’s talk about making it real. Here is the only tool we know that can really help unlock insight from all the data we collect. So when we think about improving the service for our own customers, when we think about improving operations inside the enterprise, when we think about maybe covid-19 vaccinations happening at a rate we’ve never seen, it is what helps make all of that happen. So you take that thinking. I’m really excited about open source.

500 million lines of code all collected so that we can train AI to help write code itself or programming. But imagine how much productivity that’ll unlock all you think about our auto rescue, our technology to help gather data from wherever it may reside across public clouds. These are all examples of how it really comes to life, but really helps unlock and delight and users. And I think about AI let’s unlock a little bit. That is a salesperson. They sit there and they’re trying to see what is happening to their client and Salesforce maybe. And I can look at that and say, hey, this opportunity is progressing. What should I add into that opportunity to delight the client even more? Who else should I work with inside the enterprise in order to go back? That’s what I really helps augment human intelligence. And I use the word does doesn’t replace but takes away the mundane tasks.

 

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

 

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More